{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:22:21Z","timestamp":1790734941645,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaccao.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T05:31:53Z","timestamp":1634880713000},"page":"550-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Genomic Screening for Pathogenic Transthyretin Variants Finds Evidence of Underdiagnosed Amyloid Cardiomyopathy From Health Records"],"prefix":"10.1016","volume":"3","author":[{"given":"Brendan J.","family":"Carry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Fielden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Sturm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. David","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Lester","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Fornwalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Haggerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2021.07.002_bib1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.002_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","article-title":"Amyloidosis cardiomyopathy","volume":"33","author":"Nativi-Nicolau","year":"2018","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.002_bib3","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"5345","article-title":"Amyloidosis","author":"Benson","year":"2000"},{"key":"10.1016\/j.jaccao.2021.07.002_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-01706-7","article-title":"Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups","volume":"16","author":"Rintell","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaccao.2021.07.002_bib5","first-page":"49","article-title":"Genomic screening identifies individuals at high risk for hereditary transthyretin amyloidosis","volume":"11","author":"Soper","year":"2021","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.jaccao.2021.07.002_bib6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.07.002_bib8","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41436-021-01172-3","article-title":"ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Miller","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.jaccao.2021.07.002_bib9","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2021.07.002_bib10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.07.002_bib11","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2006.01.042","article-title":"Transthyretin V122I in African Americans with congestive heart failure","volume":"47","author":"Buxbaum","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.002_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.07.002_bib13","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaccao.2021.07.002_bib14","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ajhg.2018.03.012","article-title":"Profiling and leveraging relatedness in a precision medicine cohort of 92,455 exomes","volume":"102","author":"Staples","year":"2018","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaccao.2021.07.002_bib15","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaccao.2021.07.002_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.jaccao.2021.07.002_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ajhg.2014.10.005","article-title":"PRIMUS: rapid reconstruction of pedigrees from genome-wide estimates of identity by descent","volume":"95","author":"Staples","year":"2014","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaccao.2021.07.002_bib18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)\u2217 cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.jaccao.2021.07.002_bib19","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2021.07.002_bib20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2021.07.002_bib21","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2010.02.006","article-title":"Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) studies","volume":"159","author":"Buxbaum","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jaccao.2021.07.002_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jaccao.2021.07.002_bib23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41431-019-0337-1","article-title":"Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data","volume":"27","author":"Lahuerta Pueyo","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jaccao.2021.07.002_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/art.1780300210","article-title":"Hereditary amyloidosis: description of a new American kindred with late onset cardiomyopathy","volume":"30","author":"Benson","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaccao.2021.07.002_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","article-title":"Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study","volume":"59","author":"Reilly","year":"1995","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.jaccao.2021.07.002_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1161\/CIRCGEN.119.002579","article-title":"Prevalence\u00a0and electronic health record-based phenotype of loss-of-function genetic variants in arrhythmogenic right ventricular cardiomyopathy-associated genes","volume":"12","author":"Carruth","year":"2019","journal-title":"Circ Genomic Precis Med"},{"key":"10.1016\/j.jaccao.2021.07.002_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.119.039573","article-title":"Genomics-first evaluation of heart disease associated with titin-truncating variants","volume":"140","author":"Haggerty","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.002_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.002_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015 potential underdetection of cardiac amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.002_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jaccao.2021.07.002_bib31","first-page":"709","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jaccao.2021.07.002_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.002_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.07.002_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with Hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.07.002_bib35","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.002_bib36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.002_bib37","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.002_bib38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/CS20160413","article-title":"Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy","volume":"131","author":"Galant","year":"2017","journal-title":"Clin Sci"},{"key":"10.1016\/j.jaccao.2021.07.002_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations\u2217","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2021.07.002_bib40","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","author":"Kazi","year":"2020","journal-title":"Circulation"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608732100154X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608732100154X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:54:09Z","timestamp":1762973649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266608732100154X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S266608732100154X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2021.07.002","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic Screening for Pathogenic Transthyretin Variants Finds Evidence of Underdiagnosed Amyloid Cardiomyopathy From Health Records","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2021.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}